Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?
作者信息
Yurttas Nurgul Ozgur, Eskazan Ahmet Emre
机构信息
1 Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
出版信息
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619866925. doi: 10.1177/1076029619866925.
Abstract
摘要
相似文献
1
Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619866925. doi: 10.1177/1076029619866925.
2
Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.
Platelets. 2015;26(8):809-11. doi: 10.3109/09537104.2015.1049138. Epub 2015 Jun 1.
3
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
4
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
J Oncol Pharm Pract. 2011 Sep;17(3):197-202. doi: 10.1177/1078155210378913. Epub 2010 Aug 4.
5
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Rinsho Ketsueki. 2014 Jan;55(1):130-2.
6
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.
7
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Ann Hematol. 2018 Aug;97(8):1357-1367. doi: 10.1007/s00277-018-3295-8. Epub 2018 Mar 20.
8
Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Ann Pharmacother. 2011 Jun;45(6):787-97. doi: 10.1345/aph.1P784. Epub 2011 Jun 13.
9
Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Leuk Res. 2010 Jan;34(1):123-7. doi: 10.1016/j.leukres.2009.07.009. Epub 2009 Jul 28.
10
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
N Engl J Med. 2006 Jun 15;354(24):2623-4. doi: 10.1056/NEJMc053425.
引用本文的文献
1
The state of the art in secondary pharmacology and its impact on the safety of new medicines.
Nat Rev Drug Discov. 2024 Jul;23(7):525-545. doi: 10.1038/s41573-024-00942-3. Epub 2024 May 21.
2
Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities.
Oncogene. 2023 Jun;42(22):1786-1801. doi: 10.1038/s41388-023-02701-x. Epub 2023 Apr 29.
3
Asciminib: First Approval.
Drugs. 2022 Feb;82(2):219-226. doi: 10.1007/s40265-021-01662-3.
4
Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls.
Mech Ageing Dev. 2021 Sep;198:111540. doi: 10.1016/j.mad.2021.111540. Epub 2021 Jul 6.
5
Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports.
Case Rep Hematol. 2020 Feb 10;2020:5678210. doi: 10.1155/2020/5678210. eCollection 2020.
6
Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Cancer Med. 2020 Jan;9(1):313-323. doi: 10.1002/cam4.2687. Epub 2019 Nov 12.
本文引用的文献
1
TKI-Related Platelet Dysfunction Does Not Correlate With Bleeding in Patients With Chronic Phase-Chronic Myeloid Leukemia With Complete Hematological Response.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619858409. doi: 10.1177/1076029619858409.
2
Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia.
Platelets. 2019;30(7):836-843. doi: 10.1080/09537104.2018.1501470. Epub 2018 Aug 1.
3
Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.
Clin Cancer Res. 2017 Nov 1;23(21):6697-6707. doi: 10.1158/1078-0432.CCR-16-0667. Epub 2017 Aug 18.
4
Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.
Turk J Gastroenterol. 2014 Dec;25 Suppl 1:233. doi: 10.5152/tjg.2014.5281.
5
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
Thromb Res. 2015 Jan;135(1):155-60. doi: 10.1016/j.thromres.2014.11.009. Epub 2014 Nov 18.
6
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Haematologica. 2012 Sep;97(9):1444. doi: 10.3324/haematol.2012.064618. Epub 2012 Apr 24.
7
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Blood. 2011 May 12;117(19):5198-206. doi: 10.1182/blood-2010-12-326850. Epub 2011 Mar 8.
8
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Blood. 2009 Aug 27;114(9):1884-92. doi: 10.1182/blood-2009-02-205328. Epub 2009 Jun 3.
9
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Blood. 2009 Jul 9;114(2):261-3. doi: 10.1182/blood-2008-09-180604. Epub 2009 May 4.
10
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer. 2009 Jun 1;115(11):2482-90. doi: 10.1002/cncr.24257.
Zotero 插件